SEC Form 4 · accession 0001209191-18-047466
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carrie Smith Cox
Director
Period of report
Aug 9, 2018
Accepted (ET)
Aug 17, 2018 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | — | Aug 9, 2018 | A | 5,000 | A | — | — | Common Stock | 5,000 | 5,000 | D |
| Stock Option (Right to Buy)F2 | $14.93 | Aug 9, 2018 | A | 25,000 | A | — | Aug 9, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Restricted Stock Units awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on August 9, 2019, subject to continued service on Array's board of directors.
- F2The option vests in full on August 9, 2019, subject to continued service on Array's board of directors.